Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI9090 in Advanced Solid Tumors
NCT02900157Phase 1Completed
- Sponsor
- MedImmune
- Start
- Aug 2016
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of MEDI9090 in solid tumor (advanced stage), sponsored by MedImmune. Primary endpoints: Infusion Related Reactions at 30 days and Antidrug Antibodies at 6 months. Started Aug 2016; status: completed.
02
Drugs
MEDI9090
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02900157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02900157.